Skip to main content

You’re in the
Right Place

We are the organization working to cure Rett Syndrome. As the largest worldwide funder of Rett research, we're advancing genetic medicines that target the root cause of Rett. The gene therapy programs currently in clinical trials were started and incubated at RSRT. We are the go-to partner for genetic medicine scientists and companies.

The commitment and passion of Rett families in the US and around the globe make our critical work possible. If you want a cure as urgently as we do, we welcome you to our site and invite you to join us in our quest.

Home Hdr 071124
rsrt-webinar-june2026-gfx-zoom-maincover

The Next Wave of Genetic Medicines for Rett

We had a record turnout for our recent webinar and if you missed it, the full recording is now available.

Our CEO, Monica Coenraads, was joined by her colleagues for a wide-ranging conversation on everything happening right now in genetic medicine for Rett syndrome.  The discussion introduced several biotech newcomers to the space, laid out timelines for upcoming clinical trials, and wrapped with an in-depth Q&A.

Our goal is to put ourselves out of business as quickly as possible.

curesvid-vidthumb
Roadmap to Cures 2.0

Rare diseases don’t cure themselves. Developing genetic medicines is a complex, expensive effort with many moving parts. We are the organization orchestrating this global effort. Here is our plan to cure Rett syndrome.

Recently Diagnosed?

Getting a Rett syndrome diagnosis is one of the hardest things you’ll ever face. We know this first-hand. Emotions can run the gamut and it can all seem overwhelming. You’re worried about your child and your family. You’re reading everything you can get your hands on but unsure how to interpret it or if it's relevant. We’ve been there, just reach out to us: we’ve got your back.

Bg Newly New
rettgenmed2025-teaser-9x16-v5b-thumb-web

The Summit

Over the course of three days in September we convened leading scientists, clinicians, and regulators to explore every corner of the genetic medicines landscape. The leadership from over 45 biopharma companies had a unique opportunity to hear about the state of Rett genetic medicine programs, with the ultimate goal of inspiring and motivating them to add the disorder to their pipelines.

This year’s gathering underscored RSRT’s role as both convener and catalyst, bringing brilliant minds together while never losing sight of the children and families at the heart of our community.

2 Bg

Latest News

Take Action

Asset 3

Fundraising Events

Explore the different options

Asset 2

Crowdfunding

Start a crowdfunding campaign today!

Asset 4

Register with RSRT

Join our community

MECP2 Duplication

MECP2 Duplication syndrome (MDS) is caused by a genetic error that duplicates a section of the X chromosome that includes the MECP2 gene. The MECP2 Duplication Syndrome Fund at RSRT, created in 2010, puts the intellectual and scientific resources of RSRT immediately to work for the MDS community.

Dupe

Upcoming Fundraising Events

$40M